Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Excellence in the Research Area of Multifunctional Hybrid Hydrogel-Fibrous Constructs for Wound Dressings (HyFiDress)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Destination: Improved access to Excellence
Action type: Coordination and support actions
Panel: Life Sciences
Countries involved: Poland,Germany,France,Netherlands
Call: Twinning Bottom-Up (HORIZON-WIDERA-2023-ACCESS-02, 2023)
Start date: 2024-06-01
End date: 2027-05-31
Duration (months): 36.0
Total project cost (EUR): 1506063.37
EU funding (EUR): 1498223.0
Participants: 4
Project status: SIGNED

HyFiDress aims at developing Excellence in the Research Area of Multifunctional Hybrid Hydrogel-Fibrous Constructs for Wound Dressings. This will be achieved by twinning the Warsaw University of Technology with outstanding EU institutions with high expertise in the areas of novel antimicrobial strategies and electrospinning. HyFiDress will allow the excellence development required for a consolidated strategic research approach and designing a set of guidelines for the exploitation and commercialization of the results that will have a strong regional, national and European impact. The proposal integrates synergies in complementary fields of research that include (large-scale) electrospinning technology, dual-function peptide development and microbiology, aiming to obtain scientific breakthroughs to improve the global health and economy. The objectives of this proposal are in line with the specific challenge and scope of the topic of the Twinning bottom-up call, addressing networking gaps and deficiencies between the research institutions of the Widening countries and internationally leading counterparts at EU level. This challenge is addressed by twinning WUT with leading EU research institutions: University Hospital Regensburg, an expert in the development and invention of novel antimicrobial strategies to combat biomaterial-associated infections, such as dual-function peptides and bacteriophages. They contribute with their extensive experience on the design and testing of novel antimicrobial agents in vitro and in vivo; JUNIA, an institution internationally-recognized for its excellence in the development of functional and instrumented textiles for medical and well-being applications providing decisive expertise on. Lastly, Bioprex Medical B.V., a biotechnology company that develops antibacterial coatings for medical devices, contributes with their expertise from industry IPR protection, business development, and valorization.

Keywords: wound healing,hydrogels,fibers,electrospinning,antimicrobial,multifunctional
Relicts of Ancient Cellular Biochemistry in High-CO2 Subsurface Ecosystems (Archean Park)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Synergy grants
Action type: ERC actions
Countries involved: Germany
Call: ERC Synergy Grants (ERC-2023-SyG, 2023)
Start date: 2024-05-01
End date: 2030-04-30
Duration (months): 72.0
Total project cost (EUR): 11511103.0
EU funding (EUR): 11511103.0
Participants: 4
Project status: SIGNED

The biological conversion of inorganic to organic carbon, autotrophic CO2 fixation, is arguably the most important biosynthetic process on Earth. Having been established early in the Archean Eon, a period characterized by an atmosphere rich in CO2, this metabolism helped spark and fuel the evolution of early microbial life. Mounting evidence suggests that exceedingly high levels of CO2 select for energetically efficient CO2 fixation pathways, immensely affecting carbon cycling. We hypothesize that CO2-rich subsurface ecosystems still harbor microbes that prefer or even require extremely high CO2 concentrations; we refer to these microbes as carbodioxyphiles. Accordingly, elevated CO2 levels would impact the thermodynamics of the microbial central carbon metabolism, enhancing autotrophy and hindering remineralization of organic matter by heterotrophs. To this end, we will study microbial life in CO2-rich subsurface environments and elucidate ancient metabolic pathways rendered obsolete by the CO2 levels of most modern environments. Each of the research team’s members has contributed to prior breakthroughs in novel autotrophic pathways, environmental genomics, metabolomics, and/or the biogeochemistry of deep subsurface environments. Establishing optimal synergy in this wealth of expertise and experience, we will describe novel modes of microbial carbon fixation in CO2-rich settings and elucidate the importance of carbodioxyphily for microbial evolution. Archean Park will provide a unique window through which to study a new mode of cellular biochemistry, the relicts of primordial carbon fixation, and Earth’s earliest carbon cycle. We will comprehensively characterize the metabolic mechanisms exploited by microbes to achieve evolutionary dominion in these relict environments. Our findings will stimulate biotechnological and geotechnical innovations ranging from enhanced autotrophic biomass production to improved carbon sequestration and storage.

Keywords: autotrophy,metabolism,carbon cycle,deep biosphere,microbial physiology
The role of eEF1A in synapse function, maintenance, and synucleinopathy (EaSYFUN)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: France,Germany
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-06-01
End date: 2024-11-30
Duration (months): 30.0
Total project cost (EUR): 235853.42
EU funding (EUR): 235853.42
Participants: 2
Project status: CLOSED

Synucleinopathies are neurodegenerative conditions characterized by an accumulation of the protein alpha-synuclein, including Parkinson's disease and dementia with Lewy bodies. A long asymptomatic phase precedes the onset of invalidating symptoms. Early diagnostics and treatments are hampered by an incomplete understanding of the pathophysiological mechanisms. The Host has recently identified the synaptic depletion of protein elongation factor 1A (eEF1A) at early stage of the disease. In EaSYFUN, the Fellow proposes to combine state of the art genome editing with transgenic murine disease model and human induced pluripotent stem cell derived neurons to unravel eEF1A function at synapses, characterize in depth its alterations in synucleinopathy, and question its pathophysiological role in the disease onset and progress. In Aim1 we shall provide a spatiotemporal map of eEF1A in neurons and its depletion in pathology. In Aim2 we will explore knock-down and rescue of eEF1A variants. We will test whether eEF1A depletion is necessary and sufficient to lead to all or some aspects of synucleinopathy. In Aim3 we will explore the functions of eEF1A variants at synapse (protein translation or degradation, regulation of synaptic vesicle cycle, spine structure) and the binding partners of eEF1A through proteomics. We will provide insights into the alterations of synaptic functions in synucleinopathy and the role of eEF1A. The applicant will benefit from established protocols by the Host and will bring new expertise to tackle eEF1A function at synapses with unprecedented resolution and to provide new therapeutic avenues for Synucleinopathy. EaSYFUN will benefit from an ongoing collaboration with Pr Jochen Herms (DZNE, Munich, Germany). The proposed work will expand the Fellow’s core scientific expertise, soft skills, and professional network to match her plans towards an independent academic research career.

Keywords: alpha synuclein,elongation factor 1 alpha,synapse,proteomics,synucleinopathy,crispr cas9
Hybrid Cyber Warfare and Common Security in Europe (CYBERCOMM)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Norway
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2023-09-01
End date: 2025-11-30
Duration (months): 27.0
Total project cost (EUR): 210911.04
EU funding (EUR): 210911.04
Participants: 1
Project status: SIGNED

The proposed project will address the hybridization of modern warfare, which has led to a multi-dimensional crisis both in Europe and worldwide after Russia’s invasion of Ukraine on 24 February 2022. Because these recent developments blur the dividing line between ‘war’ and ‘peace’, the project will focus on cyber warfare as a key component of multi-layered hybrid strategies employed by hostile state actors and organized criminality to undermine peace and security in Europe. Building upon the European heritage of partnerships, the main objective of this research is to develop an exemplary model of effective legal and cyber measures that can become a foundation for a common principled approach to digital-security and fundamental freedoms in Eurasian countries with varying political, social and economic settings. Aimed not only at EU member states, but also at other countries which seek closer cooperation with the European Union, the research methodology will use an interdisciplinary approach at the intersection of cyber security and law to contribute to activities that can prevent malevolent hybrid strategies from prevailing and setting an undesirable precedent for future warfare campaigns. As opposed to the predominant focus on economic, labour and social dimensions of new technologies, this novel research considers the implications of progress in terms of issues related to technological sovereignty, safety of critical infrastructure and joint defence capabilities. My integration in the interdisciplinary group on ‘crime control and security law’ at UiT the Arctic University of Norway will be instrumental in complementing my knowledge of European/International Law and transitional justice with the latest cyber security expertise, transferring it to Ukraine and other EU partner countries as well as reaching a professorship to train next generations of experts, whose intersectoral cooperation will lay the ground for a coordinated response to hybrid warfare in Europe.

Keywords: cyber crime,crime control and prevention,security law,law of war,human rights,european law,international conflict,transnational criminality,organized crime,cyber security,digitalization
Seamless design of smart edge processors (CONVOLVE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Digital
Destination: Digital & Emerging Technologies for Competitiveness and Fit for the Green Deal
Action type: Research and Innovation actions
Countries involved: Netherlands,Morocco,Belgium,Switzerland,United Kingdom,Spain,Germany,Denmark,Greece
Call: Ultra-low-power, secure processors for edge computing (RIA) (HORIZON-CL4-2021-DIGITAL-EMERGING-01, 2021)
Start date: 2022-11-01
End date: 2026-04-30
Duration (months): 42.0
Total project cost (EUR): 8418127.5
EU funding (EUR): 8416876.5
Participants: 20
Project status: SIGNED

With the rise of deep learning (DL), our world braces for Artificial Intelligence (AI) in every edge device, creating an urgent need for edge-AI processing hardware. Unlike existing solutions, this hardware needs to support high throughput, reliable, and secure AI processing at ultra-low power (ULP), with a very short time to market. With its strong legacy in edge solutions and open processing platforms, the EU is ideally positioned to become the leader in this edge-AI market. However, certain roadblocks keep the EU from assuming this leadership role: Edge processors need to become 100x more energy efficient; Their complexity demands automated design with 10x design time reduction; They must be secure and reliable to get accepted; Finally, they should be flexible and powerful to support the DL domain. CONVOLVE addresses these roadblocks and thereby enables EU leadership in Edge-AI. To that end, it will take a holistic approach with innovations at all design stack levels, including: 1.ULP memristive circuits for computation-in-memory 2.Fast compositional design of System-on-Chips (SoC) 3.Transparent compilers supporting automated code optimizations and domain-specific languages 4.Rethinking DL models through dynamic neural networks, event-based execution, and sparsity 5.On-edge continuous learning for improved accuracy, self-healing, and reliable adaptation to non-stationary environments 6.Holistic integration in SoCs supporting secure execution with real-time guarantees The CONVOLVE consortium includes some of Europe's strongest research groups and industries, covering the whole design stack and value chain. In a community effort, we will demonstrate Edge-AI computing in real-life vision and audio domains. By combining these innovative ULP and fast design solutions, CONVOLVE will, for the first time, enable reliable, smart, and energy-efficient edge-AI devices at a rapid time-to-market and low cost, and as such open the road for EU leadership in edge-processing.

Keywords: edge processing,computing in memory,secure by design,real time,deep learning,compositional design,near memory computing,ultra low power design,dynamic neuronal networks
Tree water use under changing snow/rain seasonality: The forgotten tree-induced upward preferential flow in boreal soils (BoTWU)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Finland
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2023-10-01
End date: 2025-09-30
Duration (months): 24.0
Total project cost (EUR): 215534.4
EU funding (EUR): 215534.4
Participants: 1
Project status: SIGNED

The project ‘Tree water use under changing snow/rain seasonality: The forgotten tree-induced upward fast flow in boreal soils’ aims to go beyond the state-of-the-art in boreal tree water use (TWU) research by (1) challenging the fundamental TWU assumption of no water isotope fractionation along the boreal TWU pathway, (2) unravelling the hydrological importance of the forgotten ‘upwards preferential flow’ in boreal forest soil, and (3) being the first to systematically consider biophysical impacts of changing snow and rain on TWU from the root level to individual level. Under the supervision of Prof. Hannu Marttila (University of Oulu), these aims will be supported by an innovative experiment set-up (high-resolution water isotopes and bi-directional fluxes on roots to stems) and up-to-date methodology and instruments (in-situ non-destructive Water Isotope Probes, Picarro L2140-I isotope analyzer, heat-plus-method sap flow sensors), where the research will be conducted in a boreal forest near the Arctic Circle on three typical boreal species with manipulated snowpack depth. During the project, my expertise in (eco)hydrology will expand from temperate forests and sap flow techniques to boreal forests and stable water isotope techniques, which will be a stepping stone in my long-term academic career plan for becoming a leading and independent ecohydrologist. Meanwhile, my know-how in tree transpiration and tree ecophysiology complements the expertise in northern hydrology at UOULU. The proposed dissemination, exploitation, and communication measures and activities will significantly impact the ecohydrology community and will subsequently contribute to improving sustainable-use, climate-smart forest and water resource management benefitting forest and water resource related stakeholders and lowering climate risks for society.

Keywords: tree water uptake,water isotope,sap flow,snow,rainfall,boreal forests,ecohydrologic separation
Research in Europe and Diversity Inclusion (READI)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Public-private partnerships
Destination: Innovative Health Initiative
Action type: Research and Innovation actions
Partnership: IHI (JU-JTI)
Countries involved: Spain,United Kingdom,Denmark,Belgium,Germany,Ireland,Lithuania,Italy,Portugal,Cyprus,Netherlands,Romania,United States,Sweden,Luxembourg,Switzerland,France,Brazil,Poland
Call: Inclusive clinical studies for equitable access to clinical research in Europe (HORIZON-JU-IHI-2023-04-two-stage, 2023)
Start date: 2025-01-01
End date: 2030-12-31
Duration (months): 72.0
Total project cost (EUR): 68740874.0
EU funding (EUR): 31538000.0
Participants: 80
Project status: SIGNED

The public-private partnership, READI, seeks to help clinical studies (CS) to finally serve the complete general population, and therefore more patients. To date CS have struggled to recruit and retain participants from diverse backgrounds and communities, such as marginalized or disadvantaged groups (e.g., sexual, gender, age, cultural, and socioeconomic cohorts). The resulting knowledge gaps entrench or increase health disparities. The READI consortium strives to tackle these challenges by fostering a more cohesive and integrated CS ecosystem for underserved (US) and underrepresented (UR) communities. It will actively connect all key stakeholders who can facilitate access to a wide range of patient populations. It will provide these stakeholders with the necessary tools, training programs, and approaches essential for the recruitment and retention of US/UR patients in CS. In addition, it will design, build and implement a digital platform which is patient-centred, sustainable, open and innovative. This will foster improved access to CS information and READI tools, while also supporting patient connections with the created communities. Finally, at least 4 CS will be used for testing the effectiveness of the developed tools and approaches. READI has a three-fold objective: to help US/UR communities overcome CS participation barriers (e.g., lack of information/awareness, mistrust, poor communication, geographic limitations, prejudice), which in turn will improve research of many diseases and conditions, preventative care and treatment effectiveness in different demographic groups, and better serve society. READI’s success will draw from its interdisciplinary, multi-stakeholder, consortium composition of 73 organizations from 18 countries, with key expertise in drug development and CS (design and operations), engagement strategies for US/UR populations, digital platform development, training and capability building initiatives, effective communication and dissemination, long-term sustainability, ethics and regulatory affairs.

Keywords: clinical study accessibility,patient engagement,data interoperability,digital innovation,underserved populations,underrepresented populations
SGLT2 INHIBITION FOR CARDIOVASCULAR ENDPOINT REDUCTION IN HYPERTENSION (SGLT2-HYPE) (SGLT2-HYPE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Tackling diseases and reducing disease burden
Action type: Research and Innovation actions
Countries involved: Germany,Italy,Lithuania,Netherlands,Poland,Portugal,Slovenia,United Kingdom,Austria,Czechia,Spain,France,Ukraine
Call: Comparative effectiveness research for healthcare interventions in areas of high public health need (HORIZON-HLTH-2024-DISEASE-03-two-stage, 2024)
Start date: 2025-01-01
End date: 2032-06-30
Duration (months): 90.0
Total project cost (EUR): 7297970.7
EU funding (EUR): 6999998.95
Participants: 18
Project status: SIGNED

Hypertension (HTN) is a leading cause of cardiovascular disease (CVD), affecting >80 million EU citizens and >50% of people aged >65 years, resulting in 1 million deaths per year, predominantly from CVD and chronic kidney disease (CKD). The damage done by CVD costs almost €300 billion annually in the EU alone. Despite existing therapies, patients with HTN still face substantial risks, due to pre-existing and ongoing end-organ damage due, in part, to inadequate blood pressure (BP) control. SGLT2 inhibitors (SGLT2i) are recommended for both type-2 diabetes and heart failure to reduce morbidity and mortality. SGLT2i reduce BP and might also improve outcomes for HTN by reducing end-organ damage through diverse other actions. However, confirmation that SGLT2i are clinically useful for the management of HTN is required to change guidelines and clinical practice. Therefore, we designed a multicentre, double-blind, randomised, placebo-controlled trial (SGLT2-HYPE), comparing the effects of dapagliflozin to placebo in people with inadequately controlled HTN, aged ≥65 years and with at least one other CVD or risk factor. The primary endpoint is a composite of CVD and CKD morbidity and mortality; a key secondary endpoint assesses quality of life. With 5,792 participants, assuming an annual placebo event rate of 2.5% compared to 2% with SGLT2i, a 3-year recruitment period and a minimum follow-up period of 4 years (7 years in total), the trial has 80% power for p<0.05 (two-sided). This guideline-relevant trial will inform guidelines and practice and may introduce a new therapeutic class for HTN, enhancing the current standard of care for an extremely common, treatable cause of CVD/CKD to reduce or prevent morbidity, disability and death. By engaging with key stakeholders, the trial aims to not only revolutionize care and wellbeing but also to achieve substantial healthcare cost savings (~€10 billion annually across the EU) and prevent >250,000 deaths globally each year.

Keywords: hypertension,sglt2 inhibitor,blood pressure,major adverse cardiovascular events,mortality